Liposomes as a nanoplatform to improve the delivery of antibiotics into Staphylococcus aureus biofilms

• Published in: Pharmaceutics 2021-03, Vol.13(3):321 (3), p.321
• Main Authors: Catroga Ferreira, Magda Sofia, Pinto, Sandra N., Aires da Silva, Frederico, Bettencourt, Ana, Aguiar, Sandra, Gaspar, Maria Manuela
• Format: Article
• Language: English
• Subjects: Biofilms; Infection; Liposomes; Staphylococcus aureus; Transwell model
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics13030321

Research Areas: Pharmacology & Pharmacy ABSTRACT - Staphylococcus aureus biofilm-associated infections are a major public health concern. Current therapies are hampered by reduced penetration of antibiotics through biofilm and low accumulation levels at infected sites, requiring prolonged usage. To overcome these, repurposing antibiotics in combination with nanotechnological platforms is one of the most appealing fast-track and costeffective approaches. In the present work, we assessed the potential therapeutic benefit of three antibiotics, vancomycin, levofloxacin and rifabutin (RFB), through their incorporation in liposomes. Free RFB displayed the utmost antibacterial effect with MIC and MBIC50 below 0.006 µg/mL towards a methicillin susceptible S. aureus (MSSA). RFB was selected for further in vitro studies and the influence of different lipid compositions on bacterial biofilm interactions was evaluated. Although positively charged RFB liposomes displayed the highest interaction with MSSA biofilms, RFB incorporated in negatively charged liposomes displayed lower MBIC50 values in comparison to the antibiotic in the free form. Preliminary safety assessment on all RFB formulations towards osteoblast and fibroblast cell lines demonstrated that a reduction on cell viability was only observed for the positively charged liposomes. Overall, negatively charged RFB liposomes are a promising approach against biofilm S. aureus infections and further in vivo studies should be performed.